Drug Profile


Alternative Names: ACT 058362; Urotensin II receptor antagonist - Actelion

Latest Information Update: 02 Aug 2012

Price : $50

At a glance

  • Originator Actelion Pharmaceuticals
  • Class Quinolines; Small molecules
  • Mechanism of Action Urotensin II antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cardiovascular disorders; Diabetic nephropathies

Most Recent Events

  • 19 Jul 2012 Discontinued - Phase-II for Diabetic nephropathies in Switzerland (PO)
  • 19 Jul 2012 Discontinued - Phase-II for Cardiovascular disorders in Switzerland (PO)
  • 27 May 2005 Suspended - Phase-II for Diabetic nephropathies in Switzerland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top